Payment overview · 2025
General Payments
$989.77
54 reported records · 20 companies
Healthcare provider profile · identity verified
Timothy C Mills, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LORIS, SC · NPI 1972694628
Verified facts
What the public records show
CMS Open Payments records show Timothy C Mills, M.D. received $989.77 in general payments during 2025 across 54 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 372 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 483 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $149.17 | 15.1% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.53 | 14.3% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $121.16 | 12.2% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $71.73 | 7.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.71 | 6.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.23 | 6.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.85 | 5.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.16 | 4.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.75 | 4.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.68 | 3.1% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $30.07 | 3.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.87 | 2.8% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.71 | 2.8% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $23.56 | 2.4% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $20.70 | 2.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.30 | 1.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.06 | 1.7% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $15.65 | 1.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.33 | 1.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $13.55 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $989.77 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $97.64 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $97.64 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $97.64 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $76.25 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $71.73 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.18 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.23 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.23 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $55.13 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $54.85 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $48.16 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.75 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.75 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.68 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $30.07 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.64 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.87 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.87 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $27.71 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 15 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 31 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 483 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 129 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 372 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 250 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 52 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
129 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
372 | 65 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
31 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
52 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
250 | 51 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
483 | 67 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 952 | 159 |
| Atorvastatin Calcium | Atorvastatin Calcium | 921 | 227 |
| Amlodipine Besylate | Amlodipine Besylate | 844 | 236 |
| Omeprazole | Omeprazole | 790 | 199 |
| Lisinopril | Lisinopril | 705 | 180 |
| Losartan Potassium | Losartan Potassium | 640 | 150 |
| Pantoprazole Sodium | Pantoprazole Sodium | 633 | 151 |
| Gabapentin | Gabapentin | 504 | 116 |
| Eliquis | Apixaban | 483 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 465 | 123 |
| Famotidine | Famotidine | 419 | 102 |
| Duloxetine Hcl | Duloxetine Hcl | 383 | 76 |
| Furosemide | Furosemide | 378 | 101 |
| Jardiance | Empagliflozin | 372 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 356 | 99 |
| Pravastatin Sodium | Pravastatin Sodium | 340 | 84 |
| Metformin Hcl Er | Metformin Hcl | 330 | 101 |
| Carvedilol | Carvedilol | 317 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 315 | 83 |
| Metoprolol Tartrate | Metoprolol Tartrate | 312 | 76 |
| Alprazolam | Alprazolam | 299 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 291 | 70 |
| Metformin Hcl | Metformin Hcl | 256 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 255 | 38 |
| Ozempic | Semaglutide | 250 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 245 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 245 | 60 |
| Potassium Chloride | Potassium Chloride | 244 | 72 |
| Prednisone | Prednisone | 240 | 160 |
| Clopidogrel | Clopidogrel Bisulfate | 218 | 49 |
| Doxycycline Hyclate | Doxycycline Hyclate | 206 | 167 |
| Sertraline Hcl | Sertraline Hcl | 202 | 48 |
| Mirtazapine | Mirtazapine | 191 | 39 |
| Allopurinol | Allopurinol | 177 | 51 |
| Trazodone Hcl | Trazodone Hcl | 176 | 44 |
| Simvastatin | Simvastatin | 174 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 55 |
| Valsartan | Valsartan | 148 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 142 | 41 |
| Ezetimibe | Ezetimibe | 138 | 37 |
| Ondansetron Hcl | Ondansetron Hcl | 133 | 47 |
| Cephalexin | Cephalexin | 130 | 96 |
| Farxiga | Dapagliflozin Propanediol | 129 | 26 |
| Irbesartan | Irbesartan | 128 | 38 |
| Spironolactone | Spironolactone | 124 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 42 |
| Finasteride | Finasteride | 123 | 27 |
| Donepezil Hcl | Donepezil Hcl | 120 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 119 | 22 |
| Mupirocin | Mupirocin | 119 | 70 |
| Pregabalin | Pregabalin | 116 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 113 | 24 |
| Buspirone Hcl | Buspirone Hcl | 111 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 108 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 19 |
| Montelukast Sodium | Montelukast Sodium | 106 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 104 | 21 |
| Clonazepam | Clonazepam | 100 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 96 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 41 |
| Memantine Hcl | Memantine Hcl | 95 | 17 |
| Synthroid | Levothyroxine Sodium | 93 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 92 | 21 |
| Atenolol | Atenolol | 91 | 23 |
| Lorazepam | Lorazepam | 91 | 24 |
| Myrbetriq | Mirabegron | 90 | 12 |
| Indapamide | Indapamide | 89 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 88 | 24 |
| Nifedipine Er | Nifedipine | 88 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 86 | 28 |
| Celecoxib | Celecoxib | 82 | 22 |
| Divalproex Sodium | Divalproex Sodium | 81 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 79 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 73 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 22 |
| Levetiracetam | Levetiracetam | 69 | 11 |
| Mounjaro | Tirzepatide | 69 | 12 |
| Trulicity | Dulaglutide | 69 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 67 | 17 |
| Januvia | Sitagliptin Phosphate | 66 | suppressed |
| Linzess | Linaclotide | 66 | 19 |
| Sucralfate | Sucralfate | 66 | 16 |
| Colchicine | Colchicine | 62 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 60 | 13 |
| Sotalol | Sotalol Hcl | 59 | 14 |
| Tradjenta | Linagliptin | 59 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 57 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 56 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 55 | suppressed |
| Torsemide | Torsemide | 55 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 52 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 13 |
| Fenofibrate | Fenofibrate | 50 | 11 |
| Bupropion Xl | Bupropion Hcl | 49 | 14 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Fluconazole | Fluconazole | 48 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 14 |
| Valacyclovir | Valacyclovir Hcl | 48 | 23 |
| Amoxicillin | Amoxicillin | 46 | 38 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | suppressed |
| Topiramate | Topiramate | 46 | 16 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 43 | suppressed |
| Glimepiride | Glimepiride | 43 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Glipizide | Glipizide | 39 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | 11 |
| Lovastatin | Lovastatin | 38 | 11 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | 11 |
| Novolog Flexpen | Insulin Aspart | 35 | 13 |
| Carbamazepine | Carbamazepine | 34 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 34 | 31 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | 11 |
| Primidone | Primidone | 34 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 34 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Gemtesa | Vibegron | 33 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 31 | 30 |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Rybelsus | Semaglutide | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Calcium Acetate | Calcium Acetate | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 13 |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 11 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 14 |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Travoprost | Travoprost | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Tadalafil | Tadalafil | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Betamethasone Sod Phos-Acetate | Betamethasone Acetate,sod Phos | 14 | 14 |
| Ceftriaxone | Ceftriaxone Sodium | 14 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Xanax | Alprazolam | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $989.77 · 54 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, APTIMA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ECC Solutions, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, IBSRELA, INJECTAFER, JARDIANCE, Kerendia, Korlym, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, THINPREP 2000 PROCESSOR, TRELEGY ELLIPTA, UBRELVY, WaveWriter Alpha Prime 16, Wegovy | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error